Technology | June 09, 2014

Personalized Care from Disease Detection through Treatment Assessment Enabled with GE Healthcare’s Discovery IQ

June 9, 2014 — At the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, GE Healthcare introduced its Discovery* IQ^ PET/CT (positron emission tomography/ computed tomography) system enabling both outstanding image quality and intelligent quantitation, helping physicians to deliver the best possible patient outcomes.

Discovery IQ

Physicians not only want the ability to detect smaller lesions, but also the ability to determine earlier whether the patient is responding to current treatment. With the highest sensitivity in the industry (up to 22 cps/kBq), the largest axial field-of-view (up to 26 cm) and quantitative SUV measurements physicians can trust, Discovery IQ provides an essential tool to delivering personalized patient care. It enables physicians with the ability to see smaller lesions, scan faster with lower dose and improved image quality, read more efficiently and reach more patients.

“By 2020, it’s estimated that 50 percent of people will develop cancer at some point in their lives and we also know that currently approximately 70 percent of cancer patients do not respond to their initial chemotherapy treatment,” said Steve Gray, president and CEO of GE Healthcare MICT. “I’m excited to introduce the Discovery IQ to help physicians with their primary mission of delivering the best possible patient outcomes. And, we’ve focused on designing the system to make it as accessible as possible to more people in more places, to ensure high-performance PET/CT clinical care is available to whomever needs it.”

Some key innovative features of Discovery IQ include:

  • GE Healthcare’s Q.Clear PET reconstruction technology, providing up to 2x improvement in both image quality and quantitation accuracy.
  • A fully scalable system, allowing for the ability to upgrade as department needs change.
  • This platform will be available also for the mobile market — enabling the latest technology across both fixed and mobile environments.
  • The new platform design and the new LightBurst detector technology allow for whole organ imaging via fast scans at low dose to help maximize patient comfort and safety.
  • Fast electronics and a dual acquisition channel that enables high quantitative accuracy for all clinically relevant tracers.

“As a leading U.S. academic institution with a strong international interest in oncology services, our mission is to provide high quality care to patients close to home,” said Charles Bogosta, president of UPMC’s international and commercial services division. “We are excited to see GE’s vision of quality, affordability and access so well aligned with ours in this regard.”

Q.Clear

GE Healthcare’s Q.Clear technology is a critical component of Discovery IQ. It delivers, for the first time, no trade-off between image quality and quantitative SUV measurements. By providing two times improvement in both quantitative accuracy and image quality in PET/CT imaging, this innovative new tool provides benefits to physicians across the cancer care continuum from diagnosis, staging, and treatment planning, to treatment assessment. Over the last decade, PET image reconstruction technology has been designed to provide better image quality, reduced acquisition time and lower injected dose. Current PET iterative reconstruction technologies, such as Time of Flight (TOF) and OSEM, force a compromise between image quality and quantitation. GE Healthcare’s new Q.Clear technology shows the advantage of full convergence PET imaging with no compromise between quantitation and image quality.

CortexID Suite^

CortexID software has been developed to aid physicians in the evaluation of patient pathologies via assessment and quantification of PET brain scans. The software aids in the assessment of human brain PET scans enabling automated analysis through quantification of tracer uptake and comparison with the corresponding tracer uptake in normal subjects. The resulting quantification is presented using volumes of interest, voxel-based or 3-D stereotactic surface projection maps of the brain. The package allows the user to generate information regarding relative changes in PET-FDG glucose metabolism and in PET brain amyloid load between a subject’s images and a normal database, which may be the result of brain neurodegeneration.

For more information: newsroom.gehealthcare.com

*Trademark of General Electric Co.

^ 510(k) pending at FDA. Not available for sale in the United States. Not for sale in all regions.

Related Content

Novel PET Tracer Clearly Identifies and Tracks Bacterial Lung Infection

Representative PET/CT images of 18F-FDS and 18F-FDG in inflamed mice. Mice were inoculated with dead K. pneumoniae (10^8 CFU/mL). Imaging was performed for days 1, 2, 3 and 4 using 18F-FDG and 18F-FDS. CT images showed clear inflammation on day 2 and day 3 with corresponding high 18F-FDG uptake on PET. No significant uptake of 18F-FDS was detected for any of those 4 days. Credit: J Li et al., University of Louisville School of Medicine, Louisville, Ky.

News | PET-CT | January 22, 2018
January 22, 2018 — Researchers at the University of Louisville, Kentucky, have demonstrated that a new...
PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Vital Unveils Newest Vitrea Advanced Visualization Release at RSNA 2017
Technology | Advanced Visualization | December 04, 2017
Vital Images unveiled the newest version of Vitrea Advanced Visualization software, the cornerstone of its imaging...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery
News | Molecular Imaging | October 26, 2017
The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Biodex Unveils Atomlab 500 Dose Calibrator and Wipe Test Counter
Technology | Nuclear Imaging | October 19, 2017
Biodex Medical Systems announced the full release of the Atomlab Dose Calibrator and Wipe Test Counter to the market...
ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Overlay Init